Method for authentication and determination of quantitative content of benzethonium chloride in medicinal drugs

FIELD: chemistry.

SUBSTANCE: invention relates to medicinal drug quality control and provides a method of authenticating and determining the quantitative content of benzethonium chloride in medicinal drugs, which includes separating components of the drug via high-performance liquid chromatography, where the eluent used is a mixture of acetonitrile, tetrabutylammonium hydrophosphate, disubstituted potassium phosphate and water, with content of tetrabutylammonium hydrophosphate of 2.5 mM, content of disubstituted potassium phosphate of 5 mM, wherein separation of the components of the drug is carried out with column length of 125 mm.

EFFECT: high accuracy and faster analysis since there is no need for special sample preparation.

9 ex

 

The invention relates to the field of quality control of medicines, in particular to a method of determining the authenticity and quantitative determination benzathine chloride in drugs.

There is a method of determining benzathine chloride [1], including the definition of prepared samples standard samples antimicrobial preservatives cresol, chlorocresol and benzathine chloride by high performance liquid chromatography (HPLC) with UV-detection at column [C18 (250×4.6 mm, 5 µm)] and mobile phase A containing 0.01 M potassium phosphate in water (monobasic) (pH 3,3), and mobile phase B containing methanol. The method has high accuracy cresol, chlorocresol and benzathine chloride, easily reproduced. The separation of components is possible by gradient elution of mobile phase A and B at the temperature of separation of 40°C.

A disadvantage of this known method include:

using a gradient elution;

the need for temperature control of the column and heating the mobile phase;

the applicability of the method for analysis cresol, chlorocresol and benzathine chloride only in standard samples of substances.

Closest to the claimed method is a method of determining benzathine chloride in the composition of the anthrax vaccine [2]. In the analysis of the preparation is that vaccines are a necessary preliminary sample preparation, consisting in the removal of adjuvant Alhydrogel by acidification of the studied preparation of the vaccine. Chromatography was performed isotretionin back-phase separation with a mobile phase of methanol/262 mm ammonium acetate (80/20 by vol./about.) in column [C18 (250×4.6 mm, 5 μm)] with a diode array detector. The detection limit benzathine chloride is 0.5 parts per million (ppm), and the limit of quantification is 1.5 ppm with a dynamic range of 100 ppm [2].

The disadvantages of this method include:

the need for preliminary preparation;

a long time of separation of the mixture components;

the use of a chromatographic column length 250 mm

In the analogue and the claimed invention is the same as the basic principle of determining benzathine chloride in pharmaceutical preparations using HPLC.

The objective of the invention is the reduction of analysis time benzathine chloride in drugs.

The problem is solved due to the fact that the method of analysis benzathine chloride in drugs, including the definition benzathine chloride by HPLC, provided the following differences:

the chromatographic column with the unmodified silica gel can be replaced by the column sorbents C8, phenyl or nitrile sorbents;

the mobile phase is predstavlyaet a mixture of acetonitrile and water, or methyl alcohol and water with the obligatory presence of salts tetraalkylammonium bases (tetrabutylammonium, tetradecylammonium, tetragammaton).

Changes in the type of chromatographic columns and composition of mobile phases can refuse to pre-treatment of samples before phase chromatography was carried out, or to increase the efficiency of the column samples only bred mobile phases 2-3 times.

In addition, the proposed method is characterized by the fact that in order to reduce the time of analysis reduced the length of the chromatographic column with 250 to 150-125 mm

The essence of the proposed method is as follows:

1. Liquid medications containing in its composition benzathine chloride (eye drops, solutions for intravenous and intramuscular injection), are injected directly without dilution or pre-breed mobile phases 2-3 times. The breeding of the analyzed sample is produced with the aim of improving the efficiency of chromatographic separation columns, the volume of injected sample should be increased from 20 to 50 µl. Without cultivation of the analyzed sample for some models of detectors liquid chromatograph may be unacceptable reduction in the sensitivity.

2. The mobile phase are the Wallpaper of a mixture of methyl alcohol and water in the ratio (75:25) with concentration of tetrabutylammonium mobile phase (1.25 mm or tetradecylammonium or tetragammaton with a concentration in mobile phase 0.75 mm.

As mobile phases can also be used a mixture of acetonitrile and water in a ratio of from 65:35) to (50:50) with a concentration of tetrabutylammonium mobile phase 1.3 to about 1.75 mm, or tetradecylammonium or tetragammaton with concentration 0,78-1,05 mm.

Tetraalkylated prevent the Association of the molecules benzathine in supramolecular structures in aqueous solutions and the consequence is the possibility of direct analysis of drugs without preliminary preparation of the sample.

Tetraalkylated for the preparation of mobile phases can be used in the form of hydrosulfate, hydrogen phosphates, bromides, and also in the form of salts with other anions. To improve the efficiency khromatograficheskoi column, the mobile phase may also contain equimolar amount heptanesulfonate sodium.

When applying tetraalkylammonium in the form of hydrosulfite and hydrogen phosphates of the mobile phase may also contain equimolar amount of disubstituted phosphate potassium or sodium to neutralize excess acidity salts tetraalkylammonium grounds. Thus tetraalkylated due to competitive sorption on the sorbent enhance the accuracy of benzathine when conducting Ana the API.

3. Reducing the time of the chromatography was carried out benzathine chloride is achieved through the use of columns with sorbent C8, phenyl or nitrile sorbents. Under the same conditions of chromatographia analysis on columns with these sorbents takes less time than the most commonly used in reversed-phase chromatography columns with C18 sorbents. Also to reduce the time of analysis, the length of the columns was reduced. Ceteris paribus reduce the length of the columns from 250 to 150 mm reduces the analysis time of 1.66 times.

4. Authenticity benzathine chloride in the product is confirmed based on matching retention time of the principal peak in the chromatogram of the test solution and the peak benzathine chloride in the chromatogram of standard solution sample.

5. Quantitative content benzathine chloride in the product is calculated by comparing the peak area benzathine on the chromatogram of a standard solution of known concentration and the peak area benzathine on the chromatogram of the test sample.

Between the set of essential features of the claimed object and achievable technical result there is a causal relationship, namely the use of mobile phases with salts tetraalkylammonium bases (tetrabutylammonium, tetradecylammonium, Tetra is telamonia) and the use of chromatographic columns with different types of sorbents reduces the analysis time by eliminating the stage of preparation of the sample. In this regard, it should be noted that in the way that the closest analogue (prototype) the process of preliminary preparation of the sample is subjected as samples of medicinal products and the standard solution sample benzathine chloride.

It also improves the accuracy of determining benzathine chloride in drugs by eliminating the possibility of uncontrolled loss of samples during sample preparation. By the present method sample preparation either excluded entirely or limited to breeding specimens mobile phases.

The invention provides:

1. To reduce the total analysis time of drugs in the presence of benzathine chloride.

2. To increase the accuracy of determining benzathine chloride in drugs.

3. To exclude the use of additional laboratory equipment (rotary evaporator, or other device for removal of chloroform from the analyzed samples).

4. To reduce overall labor costs as in the analysis and support operations (washing separating funnel and other laboratory glassware and the like).

Enablement of the claimed invention is shown in the following examples.

Content benzathine chloride in the samples of the medicines, in the accordance with the instructions for use of the drug, was 0.1 mg/ml

Example 1.

Analysis of the drug "Proxacin", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted in the mobile phase in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Diaster Phenyl 150×4.6 mm (5 μm).

Conditions chromatogaphy.

Mobile phase: a mixture of acetonitrile and 5 mm tetrabutylammonium hydrogen phosphate in water (65:35)

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm

The column temperature: room temperature (15 to 25°C)

The results of the chromatography was carried out.

Retention time benzathine - 2,69 min

The retention time of the standard sample benzathine chloride - 2,69

The efficiency of a chromatographic column by peak benzathine chloride - 7730 theoretical plates

The peak asymmetry factor benzathine chloride - 0,93

The peak asymmetry factor of the standard sample benzathine chloride - 0,93.

Content benzathine chloride given in experience, was 0,097 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 2.

Analysis of the drug "Proxacin", eye drops

The drug and the solution of a hundred the standard sample benzathine chloride (0.1 mg/ml), the mobile phase is not bred.

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Bond SB C8 150×4.6 mm (3.5 µm).

Conditions of chromatography.

Mobile phase: a mixture of methanol and 5 mm tetrabutylammonium hydrogen phosphate in water (75:35)

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm

The column temperature: room temperature (15 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine chloride - 4,53 min

The retention time of the standard sample benzathine chloride - 4,53 min Efficiency of the chromatographic column by peak benzathine chloride - 3720 theoretical plates

The peak asymmetry factor benzathine chloride - 1,81

The peak asymmetry factor of the standard sample benzathine chloride - 1,80.

Content benzathine chloride given in experience, was 0,092 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 3.

Analysis of the drug "Praxitelean", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted in the mobile phase in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is introduced into geostrategy installed column Luna C8(2) 150×4.6 mm (5 μm).

Conditions of chromatography.

Mobile phase: a mixture of acetonitrile and 2.5 mm tetrabutylammonium hydrogen phosphate, 2.5 mm heptanesulfonate sodium in water (65:35)

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm

The column temperature: room temperature (15 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine is 2.46 min

The efficiency of a chromatographic column by peak benzathine chloride - 7540 theoretical plates

The peak asymmetry factor benzathine chloride - 1,20

The peak asymmetry factor of the standard sample benzathine chloride - 1,20.

Content benzathine chloride given in experience, was 0,096 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 4.

Analysis of the drug "Praxitelean", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted in the mobile phase in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Luna C8(2) 150×4.6 mm (5 μm).

Conditions of chromatography.

Mobile phase: a mixture of acetonitrile and 3.7 mm tetrabutylammonium hydrogen phosphate in water (50:50)

Flow rate: 1.0 ml/min

The lengths of the wave detection: 230 nm

The column temperature: room temperature (15 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine -2,46 min

The efficiency of a chromatographic column by peak benzathine chloride - 7890 theoretical plates

The peak asymmetry factor benzathine chloride - 1,12

The peak asymmetry factor of the standard sample benzathine chloride - 1,12.

Content benzathine chloride given in experience, was 0,098 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 5.

Analysis of the drug "Proxacin", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted in the mobile phase in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Bond ST CN 150×4.6 mm, 5 ám.

Conditions of chromatography.

Mobile phase: a mixture of acetonitrile and 5 mm tetrabutylammonium hydrogen phosphate in water, 5 mm dogsleding potassium phosphate (65:35)

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm

The column temperature: room temperature (15 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine - 7,35 min

The effectiveness of chromium is tographically column peak benzathine chloride - 8290 theoretical plates

The peak asymmetry factor benzathine chloride - 1,20

The peak asymmetry factor of the standard sample benzathine chloride - 1,20.

Content benzathine chloride given in experience, was 0,099 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 6.

Analysis of the drug "Proxacin", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted in the mobile phase in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Bond ST CN 1 50×4.6 mm, 5 ám.

Conditions of chromatography.

Mobile phase: a mixture of acetonitrile and 3 mm tetradecylammonium hydrogen phosphate in water, 3 mm dogsleding potassium phosphate (65:35)

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm

The column temperature: room temperature (15 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine - 6,10 min

The efficiency of a chromatographic column by peak benzathine chloride - 7180 theoretical plates

The peak asymmetry factor benzathine chloride - 1,14

The peak asymmetry factor of the standard sample benneton what I chloride - 1,13.

Content benzathine chloride given in experience, was 0,096 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Similarly, with regard to the disclosure of the invention in the description of the specialist in this area can be obtained, performed other features of the invention covered by the claims, below.

Example 7

Analysis of the drug "Praxitelean", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted with eluent in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Luna C8 125×4.6 mm (5 μm).

Conditions of chromatography.

Eluent: a mixture of acetonitrile, 2.5 mm tetrabutylammonium hydrogen phosphate and 5 mm K2HPO4in water (65:35).

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm.

The column temperature: room temperature (20 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine chloride - 2,17 minutes

The efficiency of a chromatographic column by peak benzathine chloride - 6280 theoretical plates.

The peak asymmetry factor benzathine chloride - 1,25.

The coefficient asymmetr the peak and standard sample benzathine chloride - 1,25.

Content benzathine chloride given in experience, was 0,096 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

Example 8 (optional)

Analysis of the drug "Proxacin", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted with eluent in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Diaster Phenyl 125×4.0 mm (5 μm).

Conditions chromatogaphy.

Eluent: a mixture of acetonitrile, 2.5 mm tetrabutylammonium hydrogen phosphate and 5 mm K2HPO4in water (65:35).

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm.

The column temperature: room temperature (20 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine - 2,99 minutes

The retention time of the standard sample benzathine chloride - 2,97.

The efficiency of a chromatographic column by peak benzathine chloride - 7730 theoretical plates

The peak asymmetry factor benzathine chloride - 0,95.

The peak asymmetry factor of the standard sample benzathine chloride - 0,95.

Content benzathine chloride given in experience, was 0,097 mg/ml

Example 9

Analysis of the drug "Proxacin", eye drops.

The preparation and the standard solution sample benzathine chloride (0.1 mg/ml) pre-diluted with eluent in the ratio (1:1).

Consistently 20 µl of the preparation and the standard solution sample benzathine chloride is injected into a liquid chromatograph with an established column Hypersil BDS SWAPO 125×4.0 mm, 5 ám.

Conditions of chromatography.

Eluent: a mixture of acetonitrile, 2.5 mm tetrabutylammonium hydrogen phosphate and 5 mm K2HPO4in water (60:40).

Flow rate: 1.0 ml/min

The wavelength of detection: 230 nm.

The column temperature: room temperature (20 to 25°C).

The results of the chromatography was carried out.

Retention time benzathine - 7,41 minutes

The efficiency of a chromatographic column by peak benzathine chloride - 8290 theoretical plates.

The peak asymmetry factor benzathine chloride - 1,15.

The peak asymmetry factor of the standard sample benzathine chloride - 1,18.

Content benzathine chloride given in experience, was 0,099 mg/ml

This example shows the possibility of defining benzathine chloride in drug with sufficient accuracy.

References

1. Lee J.G. et al. Determination of three preservatives, cresol, chlorocresol and benzethonium, in drugs by high performance liquid chromatography-ultraviolet (HPLC-UV) detection //Journal of Pharmaceutical Investigation. - 2012. - V. 42. No.. 1. - P. 47-50.

<> 2. Wang H., Del Grosso A.V., May J.C. Determination of benzethonium chloride in anthrax vaccine adsorbed by HPLC //Biologicals. - 2006. - V. 34. No.. 4. - P. 257-263 (NEAREST equivalent).

The method of determining the authenticity and the amount benzathine chloride in drugs, involving separation of the components of the drug using high-performance liquid chromatography, characterized in that as eluent a mixture of acetonitrile, tetrabutylammonium hydrogen phosphate, disubstituted phosphate potassium and water content of tetrabutylammonium hydrogen phosphate in the amount of 2.5 mm, disubstituted phosphate potassium in an amount of 5 mm, and the separation of the components of the preparation is carried out at a column length 125 mm



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to a method of screening a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the capacity of the test substance to bind to cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower capacity to bind to cereblon or the fragment of cereblon compared with thalidomide.

EFFECT: improved method.

8 cl, 19 dwg, 8 ex

FIELD: medicine.

SUBSTANCE: method involves taking blood at 1 ml per a sample into the Vakutainer evacuated test tube with sprayed ethylene diaminetetraacetic acid 2.2 mg; a reference sample 1.0 ml and a sample 1.0 ml with weighted xenobiotics are taken from the total volume into the Eppendorf tubes; 30-minute incubation is followed by using a uniform procedure to prepare blood smears by applying on a dry slide to prepare a smear to be stained according to Leishman; blood corpuscles are analysed by the Zeiss light microscope at a magnification 1500. A microscope field showing echinocytes with styloid processes of the membrane not found in the reference sample is a sign of the xenobiotic membrane toxicity.

EFFECT: invention enables an instant assessment of the membrane toxicity of the substance.

FIELD: chemistry.

SUBSTANCE: lactic acid is transferred from a sample into a solution and voltammetric accumulation of lactic acid in the stirred solution is performed while bubbling with an inert gas for 30 s and with electroaccumulation potential of 1.2-1.4 V relative to a saturated silver chloride electrode on a background electrolyte of 0.1 M Na2HPO4, followed by detection of cathode peaks in differential mode of recording voltamperograms with potential sweep rate of 30-40 mV/s; concentration of lactic acid is determined from peak height in the potential range of 0.25-0.40 V by a standard addition method.

EFFECT: method is simple, does not require a large amount of reactants and labour costs.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: method consists in the application of glutationreductase and catalase enzymes as test-objects for determination of the anti-oxidant activity by the ratio of the rate of enzymatic reaction on the test-object after the substance addition and the rate of enzymatic reaction before the substance addition, which must be larger than 1. Preliminarily, before addition to an incubation medium, the samples of essential oil of Siberian fir are diluted with dimethylsulphoxide in a ratio of 1:1.

EFFECT: increased accuracy of determination.

2 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to a method of early detection of muscular degenerative diseases and to a method of prediction and/or determination of a therapeutic efficiency of a therapeutic preparation and/or a method of disease therapy by measurements of tetranor-PGDM (11,15-dioxo-9α-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid) in a subject's urine sample and comparison of its content relative to a sample, separated from a healthy individual. A muscular degenerative disease is identified in a patient if the concentration or content of tetranor-PGDM in a sample, separated in the patient is higher than the concentration or content of tetranor-PGDM in a sample, separated from a healthy individual. An efficiency of the therapeutic preparation and/or the method of therapy of the muscular degenerative disease is determined by comparison of the content of tetranor-PGDM in the sample, separated from the patient with the muscular degenerative disease before and after introduction of the therapeutic preparation. If the measured content of tetranor-PGDM in the sample considerably or inconsiderably decreases after the introduction of the therapeutic preparation, the method of therapy is efficient. The invention also relates to a set for diagnostics of muscular degenerative diseases, which includes an antibody to tetranor-PGDM, labelled tetranor-PGDM and optionally, at least, one compound, selected from a group, consisting of an antibody to immunoglobulin, a diluting solution for the sample, a diluting solution for the antibody and labelled tetranor-PGDM, tetranor-PGDM standard of the known concentration, a substrate for an enzyme immunoassay and a stopping solution for the enzyme immunoassay.

EFFECT: invention is efficient and simple in implementation.

7 cl, 1 tbl, 1 ex, 2 dwg

FIELD: chemistry.

SUBSTANCE: method of codeine identification includes separation of mixture components by a method of thin-layer chromatography with separation of a chromatographic zone of codeine by a reagent of Dragendorff, and quantitative determination of codeine is carried out in an area of its manifested zone directly in a solid phase by measuring diffusion reflection coefficient at a wave length of 520 nm.

EFFECT: reduction of time of identification and quantitative determination of codeine, reduction of the process labour consumption, reduction of a probability of the target component loss.

2 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a preparation for involving a mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow, which is introduced into the blood vessel or muscle and which contains any of components: (a) protein HMGB1; (b) HMGB1 protein-secreting cell; (c) a vector, into which HMGB1 protein-coding DNA is inserted; (d) protein HMGB2; (e) HMGB2 protein-secreting cell; (f) a vector, into which HMGB2 protein-coding DNA is inserted; (g) protein HMGB3; (h) HMGB3 protein-secreting cell; and (i) a vector, into which HMGB3 protein-coding DNA is inserted.

EFFECT: elaboration of the preparation for involving the mesenchymal stem cell of the bone marrow into peripheral blood from the bone marrow.

3 cl, 6 ex, 1 tbl, 14 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and describes a method for testing a planned or known immunomodulatory agent for T-cell activation which involves the stage of contacting a peripheral blood mononuclear cell (PBMC) culture with the pre-determined amount of the planned or known immunomodulatory agent in vitro and observing the T-cell activation in the PBMC culture using a readout system, when contacting the planned or known immunomodulatory agent, wherein the PBMC culture density at the stage of pre-culture makes at least 2×106/ml, preferentially at least 5×106/ml, more preferentially at least 107/ml, or at least 4×105/cm2, preferentially at least 106/cm2, most preferentially at least 2×106/cm2; the PBMC pre-culture is cultured for at least 12 hours.

EFFECT: invention provides the improved agent for testing the immunomodulatory agents in vitro.

10 cl, 16 dwg, 13 ex

FIELD: medicine.

SUBSTANCE: method concerns quantitative picamilon measurement. Solutions of a measured substance (concentration of 0.00002 g/ml) and a reference sample are prepared. A solvent for preparing the measured solutions is presented by 0.1 M sodium hydroxide. The reference sample is methyl orange. An optical density of the solution of the measured substance and the reference sample is measured in a spectrophotometer at an analytical wave length of 261 nm. The results are calculated by formula with recalculation factor 0.7505 introduced therein.

EFFECT: method allows for increasing reproducibility of the measurement results, reducing cost price, labour-intensiveness and analysis error, and unifying the analysis procedure.

4 ex

FIELD: chemistry.

SUBSTANCE: method involves extraction preparation of a sample of biological material, centrifuging and performing analysis on a capillary electrophoresis system in a quartz capillary with an effective length of 0.5 m and inner diameter of 75 mcm, wherein analysis is performed using an aqueous main electrolyte which contains 0.28% boric acid and 0.04% sodium tetraborate, with positive voltage polarity and detection wavelength of 254 nm.

EFFECT: rapid and reliable quantitative determination of indolyl-acetic acid by capillary electrophoresis using nontoxic and readily available reactants for analysis.

6 ex, 1 tbl, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves retrobulbar administration of dexamethasone, intramuscular administration of cerebrolysin and proserine, intravenous administration of nootropil. The preparations are introduced for 10 days. Administration further is followed by a percutaneous transcranial pulse magnetic stimulation and an electric stimulation of the optic nerve once a day for 10 days. The magnetic stimulation is performed at the magnetic field strength 2 T, modulation frequency 1 Hz. The exposure covers four points in the projection of the optical nerve sequentially: eyes, temporal region, postaural region, inion - for 5 minutes on each point. The electric stimulation represents the exposure to negative train pulses a frequency of which is equal to a patient's pulse rate at an electrical characteristic not less than 10-15 mC per one session.

EFFECT: method prolongs the remission of optical neuritis in the patients suffering multiple sclerosis.

2 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: composition includes a bactericidal substance - catapol - in amount of 2.1-2.5 wt %, zosterin in amount of 1.1-5.0 wt % and distilled water.

EFFECT: providing a composition which stimulates a reparative process in external protective tissue, having anti-inflammatory and radioprotective action.

1 tbl, 1 ex

FIELD: chemistry, pharmacology.

SUBSTANCE: invention relates to field of pharmacology and medicine and deals with application of halogenides of 1,3-disubstituted 2-aminobenzimidazolium, of general formula I as inhibitors of Na+/H+-exchange, as well as novel 1,3-disubstituted halogenides of 2- aminobenzimidazolium.

EFFECT: increased efficiency of inhibitors.

3 cl, 1 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: claimed compound can be used in case of diseases and states, such as tinnitus, neuropathic pain and in treatment of Alzheimer's diseases. Method includes stage (1): interaction of 1-amino-1,3,3,5,5-pentamethylcyclohexane with methanesulfonic acid in anisole at temperature from 50°C to 100°C and ratio of anisole volume to weight of 1-amino-1,3,3,5,5-pentamethylcyclohexane from 5 to 15 ml of anisole per gram of 1-amino-1,3,3,5,5-pentamethylcyclohexane. Solvent can contain dissolved in it water. Metod can also include stage (ii): separation of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate from reaction mixture of stage (i) by crystallisation with decrease of temperature in the range from -20°C to 50°C. Additionally, after stage (i) or stage (ii), method can include at least one of stages (iii)-(v). Stage (iii) consists in recrystallisation of product, formed at stage (i) or stage (ii) from anisole; stage (iv) includes addition of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate at any of preceding stages (i)-(iii); and stage (v) ingludes deagglomeration and/or crushing product, formed at any of preceding stages (i)-(iv). Crystals, obtained at stage (iv) are star-shaped. At stage (ii) or at stage (iv) also obtained are particles of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate, where less than 15% in weight of particles have particle size 10 mcm and less or where less than 10% in weight of particles have particle size 10 mcm and less. Before separation of 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate, mixture, obtained at stage (i), (ii) or (iii), is usually cooled to room temperature or below room temperature at rate of cooling from 0.05°C/min to 2°C/min.

EFFECT: invention relates to improved method of obtaining 1-amino-1,3,3,5,5-pentamethylcyclohexane mesylate.

11 cl, 6 dwg, 2 tbl, 22 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely neurology, physiotherapy. The solution of proserine is introduced 30 minutes before conducting low intensity electrical stimulation. Amplitude of the electrical stimulation is 10-20 mA, frequency is 40-40 Hz, and length is 900 seconds.

EFFECT: method reduces the length of treatment, raises muscle tone, desensitizes the peripheral innervation region.

3 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and describes a disulphiram implant for treating the alcohol or opiate addictive patients. The implant contains disulphiram 95.0-59.0 wt %, nitrogen polymer composition 4.8-40.5 wt % and stearic acid or magnesium stearate 0.2-0.5 wt %. The nitrogen polymer composition contains N-vinylpyrrolidone and 2-methyl-5-vinylpyridine copolymer or salts of branched oligomers hexamethylene diamine and guanidine, and polyvinylpyrrolidone.

EFFECT: implant may be used in addictology and provides a prolonged and uniform release of disulphiram with improving incisional wound healing.

5 ex, 2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to ophthalmology, and can be used for treating luetic optic neuropathy. That is ensured by subconjunctival administration of Cefazolin 0.3-0.5 mg. That is combined with intramuscular injection of Gliatilin 2.0-4.9 ml, 1-3% Glutoxim 2.0 ml and Milgamma 1.0-2.0 ml. Dexazon 0.5 ml is introduced parabulbarly. The preparations are introduced once a day for 10 days. Additionally, starting with the first therapeutic day, 10 sessions of percutaneous transcranial magnetic stimulation of the optic nerves are conducted daily.

EFFECT: method provides improving the visual functions and eliminating the complications of the central nervous system due to the integrated treatment developed with the severity of the pathological process in these patients.

1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and aims at treating acute alcoholic enteritis. Gastric lavage, ample drinking, intravenous infusions of normal saline or 5% glucose are prescribed. At admission to hospital, the patient is additionally examined for blood triglycerides. If the value is more than 2.5 mmole/l, the antibiotics are withdrawn, while the preparations of lipoic acid 900 mg before meals are prescribed within the 7-day course.

EFFECT: method enables reducing side effects of the therapy of acute alcoholic enteritis.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of ophthalmology. Ophthalmological medication in form of eye drops, contains 0.2-0.5 wt % of disulfiram, dissolved in pharmaceutically acceptable water-based carrier, 0.5-2.0 wt % of hydroxypropyl cyclodextrin, 2.0-5.0 wt % of taurine; agent, which ensures required resin condition, containing sodium chloride, sodium monohydrophosphate and dihydrophosphate, and methylparaben (nipagin) as a preservative.

EFFECT: invention ensures effective treatment of pathological conditions of eyes, such as cataract, glaucoma, ophthalmological hypertension and traumatic injuries of cornea, extends arsenal of existing preparations in form of eye drops.

6 cl, 5 tbl, 2 dwg, 5 ex

Novel methods // 2484821

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: the use of aclidinium for preparing a medicine for treating or preventing a respiratory disease or condition in a patient by inhalation, wherein said patients showed no systemic antimuscarinic actions, where the patient suffers a condition or is susceptible thereto, which may be exacerbated by systemic antimuscarinic activity (versions), and a related method of treating or preventing.

EFFECT: invention provides local therapeutic action of aclidinium in lungs and has no significant systemic antimuscarinic action as it quickly hydrolysed in blood plasma, and its main metabolites are completely deprived of affinity to muscarinic receptors.

13 cl, 3 ex

FIELD: agriculture, animal husbandry, organic chemistry.

SUBSTANCE: antiseptic ointment comprises cationic surface-active substance, lower glycols, polyethylene glycols, water and ethylene glycol monophenolic ester and higher polyethylene glycols taken in the definite ratio of components. As cationic surface-active substance ointment comprises N-alkyl-N-alkoxycarbonylmethylhexahydroazipinium chloride or alkyldimethylbenzylammonium chloride, or cetylpyridinium bromide, or cetylpyridinium chloride, or 1,2-ethylenebis-(N-methylcarbdecyloxymethyl)ammonium dichloride, or ethylhexadecyldimethylammonium chloride, or chlorhexidine; as lower glycol ointment comprises 1,2-propylene glycol or polyethylene glycol-300, or polyethylene glycol-400; as higher polyethylene glycol ointment comprises polyethylene glycol-1500 or polyethylene glycol-3000, or polyethylene glycol-4000, or polyethylene glycol-6000. Ointment elicits the high antibacterial activity, broad spectrum of bactericidal effect and low irritating effect with respect to udder skin. Invention can be used for sanitary-hygienic treatment of udder of lactating cows for prophylaxis and rapid healing external damages of udder and nipples (arising cracks), prophylaxis of mastitis, enhancing milk purity by microbiological indices.

EFFECT: valuable antiseptic properties of ointment.

2 cl, 1 tbl, 22 ex

Up!